Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Asset Writedowns and Impairment (2024)

Historic Asset Writedowns and Impairment for Zevra Therapeutics (ZVRA) over the last 2 years, with Q2 2025 value amounting to $58.7 million.

  • Zevra Therapeutics' Asset Writedowns and Impairment rose 173468.75% to $58.7 million in Q2 2025 from the same period last year, while for Sep 2025 it was $61.2 million, marking a year-over-year increase of 107715.38%. This contributed to the annual value of $5.7 million for FY2024, which is N/A changed from last year.
  • As of Q2 2025, Zevra Therapeutics' Asset Writedowns and Impairment stood at $58.7 million, which was up 173468.75% from $502000.0 recorded in Q4 2024.
  • In the past 5 years, Zevra Therapeutics' Asset Writedowns and Impairment ranged from a high of $58.7 million in Q2 2025 and a low of $502000.0 during Q4 2024